glp-1 and alzheimer's drugs failed to slow in two big clinical trials Neuroprotective Actions of Glucagon-Like Peptide-1

14 lb (1 or 2 steps?) b

Prophylactic and therapeutic vaccine development: advancements and challenges

The most commonly reported side effects include mild headache, temporary water retention, redness at the injection site, and occasional fatigue during the first week or two as the body adjusts

J Am Soc Nephrol 2019;30:2229-42.ArticlePubMedPMC 43

Treatments launched in the past several years by companies including Eli Lilly and an Eisai-Biogen partnership are the first drugs ever shown to slow cognitive decline in people with Alzheimers after years of failed trials, but they require infusions or injections and can cause significant side effects.

Growth hormone supports collagen production, skin elasticity, and cellular regeneration for a more youthful appearance